Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Oncology · Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

Systemic Therapies: Chemotherapy, Immunotherapy, and Targeted Treatments

At a Glance

The standard first-line treatment for advanced gallbladder and bile duct cancer is triple therapy, combining chemotherapy with immunotherapy. Next-Generation Sequencing (NGS) testing is essential to find specific tumor mutations and unlock personalized, targeted therapy options.

When surgery isn’t the immediate option, systemic therapies—treatments that travel through the entire body—become the backbone of your care. In recent years, this field has shifted from a “one-size-fits-all” chemotherapy approach to a more personalized strategy that combines traditional drugs with immunotherapy and precision-targeted treatments [1][2].

First-Line Treatment: The New Standard

For most patients with advanced gallbladder or bile duct cancer, the first step is a combination of three drugs. This is often called “triple therapy.”

  • The TOPAZ-1 and KEYNOTE-966 Protocols: Research has proven that adding an immunotherapy drug (either Durvalumab or Pembrolizumab) to the traditional chemotherapy pair of Gemcitabine and Cisplatin helps patients live longer than chemotherapy alone [3][4].
  • How it Works: While chemotherapy directly attacks cancer cells, immunotherapy “unmasks” the cancer so your own immune system can recognize and destroy it [5][6].
  • Maintenance: If the cancer responds well, you may eventually stop the chemotherapy and continue only the immunotherapy as “maintenance” to keep the cancer at bay with fewer side effects [3].

What to Expect: Side Effects of Triple Therapy

Knowing survival statistics is only half the battle; knowing how treatment affects your daily life is just as important.

  • Chemotherapy Side Effects: Cisplatin is known to cause neuropathy (tingling or numbness in the fingers and toes), nausea, and kidney irritation. Gemcitabine can lower your white blood cell count and cause significant fatigue.
  • Immunotherapy Risks: Immunotherapy carries unique “immune-mediated” risks. Because your immune system is amplified, it can sometimes attack healthy organs. If you experience severe diarrhea, unexpected shortness of breath, or a sudden rash, you must report this to your oncologist immediately.

Second-Line and Beyond: What Happens Next?

If the first-line treatment stops working, doctors move to a second-line therapy.

  • FOLFOX: A combination of 5-fluorouracil and oxaliplatin. It is a standard choice that has been shown to improve survival in patients who have already had Gemcitabine and Cisplatin [7][8].
  • NALIRIFOX / Liposomal Irinotecan: Newer studies show that combinations using liposomal irinotecan (a more stable version of a common chemotherapy drug) may be even more effective for some patients [9][10].

The Power of Precision: Targeted Therapies

Perhaps the most important advancement in these cancers is the rise of Targeted Therapy. These drugs are designed to home in on specific “glitches” in the cancer’s DNA. To find these glitches, your doctor must perform Next-Generation Sequencing (NGS) on your tumor tissue [11][12].

How is NGS done? The lab can often use tissue already collected during an earlier biopsy (like during an ERCP or EUS). However, if that sample was too small, you may need a new biopsy specifically for genetic testing.

Target/Biomarker Drug Example Most Common In…
FGFR2 Fusion Pemigatinib / Futibatinib Intrahepatic Cholangiocarcinoma (iCCA) [13]
IDH1 Mutation Ivosidenib Intrahepatic Cholangiocarcinoma (iCCA) [14]
HER2 Amplification Trastuzumab / Deruxtecan Gallbladder Cancer (GBC) [15][16]
BRAF V600E Dabrafenib + Trametinib Various Biliary Subtypes [17]
MSI-H / dMMR Pembrolizumab Rare in all subtypes [18]

Differences Between GBC and eCCA

While both Gallbladder Cancer (GBC) and Extrahepatic Cholangiocarcinoma (eCCA) (an umbrella term that includes both perihilar and distal cholangiocarcinoma) use the same starting chemotherapy, their underlying “blueprints” differ [19].

  • GBC is more likely to have HER2 mutations, making HER2-targeted drugs a vital consideration for these patients [20][21].
  • eCCA can be more difficult to treat with systemic therapy alone and often requires a closer partnership with radiation oncologists or surgeons to manage local blockages in the bile ducts [22][23].

Because approximately half of all biliary cancer patients have at least one targetable mutation, getting your NGS results back is as important as any scan or blood test [1][2].

Common questions in this guide

What is the first-line treatment for advanced gallbladder or bile duct cancer?
The standard first-line treatment is often a combination of three drugs, known as triple therapy. This typically includes two chemotherapy drugs, Gemcitabine and Cisplatin, combined with an immunotherapy drug like Durvalumab or Pembrolizumab.
Why is genetic testing important for biliary tract cancers?
Genetic testing, such as Next-Generation Sequencing (NGS), is crucial because it looks for specific mutations in your tumor's DNA. Discovering these mutations helps your oncologist determine if you are a candidate for targeted therapies designed specifically for your cancer type.
What are the side effects of triple therapy?
Common chemotherapy side effects include neuropathy (numbness in fingers and toes), fatigue, nausea, and kidney irritation. Immunotherapy can cause your immune system to attack healthy organs, so you should immediately report severe diarrhea, shortness of breath, or sudden rashes to your doctor.
What happens if the first chemotherapy treatment stops working?
If the initial treatment is no longer effective, doctors typically move to second-line therapies. Common options include FOLFOX or liposomal irinotecan (NALIRIFOX) combinations, which have been shown to help patients who have already received first-line treatments.
Are systemic treatments different for gallbladder cancer (GBC) versus extrahepatic cholangiocarcinoma (eCCA)?
While both cancers often start with the same standard chemotherapy, their underlying genetics differ. For example, gallbladder cancer is more likely to have HER2 mutations, making HER2-targeted drugs an important personalized option for those patients.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Will we be starting with the 'triple therapy' (Gemcitabine, Cisplatin, and an immunotherapy drug like Durvalumab or Pembrolizumab)?
  2. 2.Has my tumor been tested via Next-Generation Sequencing (NGS) for mutations like IDH1, FGFR2, HER2, and BRAF V600E?
  3. 3.If standard chemotherapy stops working, is NALIRIFOX or FOLFOX the preferred second-line option for my specific case?
  4. 4.Based on my cancer subtype (GBC or eCCA), are there certain targeted therapies that are more likely to work for me?
  5. 5.Are there any open clinical trials for the specific mutations found in my NGS report?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine.

    Mie T, Sasaki T, Okamoto T, et al.

    Cancers 2024; (16(5)) doi:10.3390/cancers16050879.

    PMID: 38473240
  2. 2

    Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms.

    Choucair K, Chamseddine S, Azmi A, Philip PA

    Frontiers in oncology 2026; (16()):1769447 doi:10.3389/fonc.2026.1769447.

    PMID: 41756323
  3. 3

    Durvalumab: A Review in Advanced Biliary Tract Cancer.

    Fung S, Syed YY

    Targeted oncology 2023; (18(6)):965-972 doi:10.1007/s11523-023-01007-y.

    PMID: 37943483
  4. 4

    Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Kelley RK, Ueno M, Yoo C, et al.

    Lancet (London, England) 2023; (401(10391)):1853-1865 doi:10.1016/S0140-6736(23)00727-4.

    PMID: 37075781
  5. 5

    Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.

    Oh DY, He AR, Qin S, et al.

    Journal of hepatology 2025; (83(5)):1092-1101 doi:10.1016/j.jhep.2025.05.003.

    PMID: 40381735
  6. 6

    Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.

    Piha-Paul SA, Oh DY, Ueno M, et al.

    International journal of cancer 2020; (147(8)):2190-2198 doi:10.1002/ijc.33013.

    PMID: 32359091
  7. 7

    Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.

    Lamarca A, Palmer DH, Wasan HS, et al.

    The Lancet. Oncology 2021; (22(5)):690-701 doi:10.1016/S1470-2045(21)00027-9.

    PMID: 33798493
  8. 8

    Chemotherapy for Biliary Tract Cancer in 2021.

    Sasaki T, Takeda T, Okamoto T, et al.

    Journal of clinical medicine 2021; (10(14)) doi:10.3390/jcm10143108.

    PMID: 34300274
  9. 9

    Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.

    Yoo C, Kim KP, Jeong JH, et al.

    The Lancet. Oncology 2021; (22(11)):1560-1572 doi:10.1016/S1470-2045(21)00486-1.

    PMID: 34656226
  10. 10

    Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials.

    Yoo C, Saborowski A, Hyung J, et al.

    Journal of hepatology 2025; (83(4)):909-916 doi:10.1016/j.jhep.2025.03.013.

    PMID: 40147791
  11. 11

    Genetic analysis in the clinical management of biliary tract cancer.

    Wakai T, Nagahashi M, Shimada Y, et al.

    Annals of gastroenterological surgery 2020; (4(4)):316-323 doi:10.1002/ags3.12334.

    PMID: 32724874
  12. 12

    How I treat biliary tract cancer.

    Lamarca A, Edeline J, Goyal L

    ESMO open 2022; (7(1)):100378 doi:10.1016/j.esmoop.2021.100378.

    PMID: 35032765
  13. 13

    Current challenges to underpinning the genetic basis for cholangiocarcinoma.

    Cigliano A, Chen X, Calvisi DF

    Expert review of gastroenterology & hepatology 2021; (15(5)):511-526 doi:10.1080/17474124.2021.1915128.

    PMID: 33888034
  14. 14

    Paradigm shift of chemotherapy and systemic treatment for biliary tract cancer.

    Leowattana W, Leowattana T, Leowattana P

    World journal of gastrointestinal oncology 2023; (15(6)):959-972 doi:10.4251/wjgo.v15.i6.959.

    PMID: 37389105
  15. 15

    Addition of trastuzumab emtansine (T-DM1) in a human epidermal growth factor receptor 2-overexpressed metastatic carcinoma of the gallbladder patient to enhance survival: A case study.

    Lavingia V, Thummar V, Mehta P

    SAGE open medical case reports 2022; (10()):2050313X221137447 doi:10.1177/2050313X221137447.

    PMID: 36467008
  16. 16

    HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

    Galdy S, Lamarca A, McNamara MG, et al.

    Cancer metastasis reviews 2017; (36(1)):141-157 doi:10.1007/s10555-016-9645-x.

    PMID: 27981460
  17. 17

    Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.

    Subbiah V, Lassen U, Élez E, et al.

    The Lancet. Oncology 2020; (21(9)):1234-1243 doi:10.1016/S1470-2045(20)30321-1.

    PMID: 32818466
  18. 18

    Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments.

    Cowzer D, Harding JJ

    Cancers 2022; (14(7)) doi:10.3390/cancers14071800.

    PMID: 35406572
  19. 19

    Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis.

    Azizi AA, Lamarca A, McNamara MG, Valle JW

    Critical reviews in oncology/hematology 2021; (163()):103328 doi:10.1016/j.critrevonc.2021.103328.

    PMID: 33862244
  20. 20

    Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients.

    de Bitter TJJ, de Reuver PR, de Savornin Lohman EAJ, et al.

    NPJ precision oncology 2022; (6(1)):83 doi:10.1038/s41698-022-00327-y.

    PMID: 36335173
  21. 21

    Anti-Human Epidermal Growth Factor Receptor-2 Therapies in Biliary Tract Cancers: A Meta-Analysis on Disease Location, Human Epidermal Growth Factor Receptor-2 Status, and Survival Outcomes.

    Camera S, Rimini M, Foti S, et al.

    Oncology 2026; (104(3)):306-318 doi:10.1159/000545308.

    PMID: 40418900
  22. 22

    Comparison of clinical features by primary site in patients with biliary tract cancer who received gemcitabine-based chemotherapy: an exploratory analysis of JCOG1113.

    Suzuki Y, Ikeda M, Mizusawa J, et al.

    International journal of clinical oncology 2025; (30(10)):2053-2062 doi:10.1007/s10147-025-02834-x.

    PMID: 40705162
  23. 23

    Predicting treatment response to systemic therapy in advanced gallbladder cancer using multiphase enhanced CT images.

    Wu J, Zheng Z, Li J, et al.

    European radiology 2025; (35(11)):7410-7420 doi:10.1007/s00330-025-11645-7.

    PMID: 40341972

This page provides educational information about systemic therapies for gallbladder and biliary tract cancers. Always consult your oncology team to determine the best treatment plan for your specific diagnosis.

Get notified when new evidence is published on Carcinoma of gallbladder and extrahepatic biliary tract.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.